RCS - Cohen Milstein - Northwest Bio Files Market Manipulation Lawsuit

Canaccord GenuityAnnouncement

02/12/2022 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221202:nRSB4878Ia&default-theme=true

RNS Number : 4878I  Cohen Milstein Sellers & Toll PLLC  02 December 2022

 

DECEMBER 02, 2022

FOR IMMEDIATE RELEASE

Press Contact:

Tess Roy, cohenmilstein@berlinrosen.com
(mailto:cohenmilstein@berlinrosen.com) , 561-596-6443

Northwest Biotherapeutics Files Manipulation Suit

Trading data shows that seven preeminent market makers engaged in market
manipulation via spoofing to drive down Northwest Biotherapeutics' stock
prices as the company worked to raise funds to bring breakthrough cancer
treatments to market

NEW YORK, NY -Northwest Biotherapeutics (OTCQB: NWBO), a clinical stage
biotechnology company focused on the development of DCVax® personalized
cancer vaccines, filed a lawsuit in New York federal court against market
makers Citadel Securities LLC, Canaccord Genuity LLC, G1 Execution Services
LLC (a subsidiary of Susquehanna International Group), GTS Securities LLC,
Virtu Americas LLC (including Knight Securities), Instinet LLC, and Score
Priority Corp.

The lawsuit, Northwest Biotherapeutics, Inc. v. Canaccord Genuity LLC, et al.,
Case No. 1:22-cv-10185
(https://www.cohenmilstein.com/sites/default/files/NWBO%20Complaint-%20Filed%2012012022.pdf)
, was filed with United States District Court for the Southern District of New
York, citing violations of Section 10(b), Rule 10b-5 and Section 9(a)(2) of
the Securities Exchange Act of 1934. The alleged actions also constitute as
fraud under New York state common law.

The announcement of the lawsuit can be accessed here
(https://www.cohenmilstein.com/update/northwest-biotherapeutics-files-lawsuit-against-major-market-makers-market-manipulation)
.

Northwest Biotherapeutics is represented by U.S. law firm Cohen Milstein
Sellers & Toll PLLC.

###

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc (https://nwbio.com/)  is a clinical-stage
biotechnology company specializing in developing cutting-edge cancer vaccines
that are designed to treat a wide range of solid tumor cancers more
effectively than the current treatments on the market and without the side
effects of chemotherapy. The company has a broad platform technology for
DCVax(®) dendritic cell-based vaccines, including DCVax(®)-L for operable
tumors and DCVax(®)-Direct for inoperable tumors. The company's proprietary
manufacturing technology allows efficient and cost-effective production of
these innovative vaccines, with the full set of multi-year doses produced in
one manufacturing batch and then stored frozen in single doses, making the
treatment "off the shelf" throughout the treatment regimen while also being
fully personalized.

About Cohen Milstein Sellers & Toll

Cohen Milstein Sellers & Toll PLLC (https://www.cohenmilstein.com/)  is
recognized as one of the premier law firms in the country handling major,
complex plaintiff-side litigation. With more than 100 attorneys, Cohen
Milstein has offices in Washington, D.C.; Chicago, Ill.; New York, N.Y.; Palm
Beach Gardens, Fla.; Philadelphia, Pa.; and Raleigh, N.C. For additional
information, visit www.cohenmilstein.com (http://www.cohenmilstein.com/)  or
call 202.408.4600.

Disclaimer

Statements made in this news release that are not historical facts, including
statements concerning future treatment of patients using DCVax and future
clinical trials, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "design," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. We cannot guarantee that we actually will achieve the
plans, intentions or expectations disclosed in our forward-looking statements
and you should not place undue reliance on our forward-looking statements.
Actual results may differ materially from those projected in any
forward-looking statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from those
anticipated, such as risks related to the Company's ability to achieve timely
performance of third parties, risks related to whether the Company's products
will demonstrate safety and efficacy, risks related to the Company's ongoing
ability to raise additional capital, and other risks included in the Company's
Securities and Exchange Commission ("SEC") filings. Additional information on
the foregoing risk factors and other factors, including Risk Factors, which
could affect the Company's results, is included in its SEC filings. Finally,
there may be other factors not mentioned above or included in the Company's
SEC filings that may cause actual results to differ materially from those
projected in any forward-looking statement. The Company assumes no obligation
to update any forward-looking statements as a result of new information,
future events or developments, except as required by securities laws.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUUOSRUVUURAA